Table 1.
Patient characteristics
| Patient (age / sex) | ALT (10–45) | Treated | Genotype | Histology (Ishak) | MLR | Phenotype | Cytokine secretion | Melan-A priming | Control (age / sex) |
|---|---|---|---|---|---|---|---|---|---|
| HCV-1 (49 / M) | 120 | No | 3 | 6 / 6 (F) 8 / 18 (I) | + | + | + | − | HI-1 (39 / M) |
| HCV-2 (40 / M) | 24 | No | ND | 1 / 6 (F) 4 / 18 (I) | + | + | + | − | HI-2 (38 / F) |
| HCV-3 (37 / F) | 34 | No | 1 | 2 / 6 (F) 4 / 18 (I) | + | + | + | − | HI-3 (34 / F) |
| HCV-4 (47 / M) | 27 | No | 3 | 2 / 6 (F) 5 / 18 (I) | + | + | + | − | HI-4 (38 / M) |
| HCV-5 (48 / F) | 41 | No | ND | 1 / 6 (F) 2 / 18 (I) | + | − | − | − | HI-5 (36 / M) |
| HCV-6 (44 / F) | 29 | No | 1 | ND | + | + | − | − | HI-6 (26 / M) |
| HCV-7 (63 / F) | 22 | No | 5a | 2 / 6 (F) 2 / 18 (I) | + | − | − | − | HI-7 (36 / F) |
| HCV-8 (42 / M) | 61 | No | 1 | 1 / 6 (F) 3 / 18 (I) | − | − | + | − | HI-8 (37 / F) |
| HCV-9 (38 / M) | 21 | No | 2b | ND | − | − | − | + | HI-5 (36 / M) |
| HCV-10 (47 / F) | 42 | No | 1a / 1b | 0 / 6 (F) 3 / 18 (I) | − | − | − | + | HI-8 (37 / F) |
| HCV-11 (36 / F) | 49 | No | ND | 1 / 6 (F) 2 / 18 (I) | − | − | − | + | HI-9 (36 / F) |
| HCV-12 (41 / F) | 28 | No | 1 | 1 / 6 (F) 3 / 18 (I) | − | − | − | + | HI-9 (36 / F) |
| HCV-13 (41 / M) | 61 | No | 1 | 1 / 6 (F) 3 / 18(I) | − | − | − | + | HI-8 (37 / F) |
13 patients were recruited consecutively from outpatients and paired with healthy controls for subsequent assays. + / − indicates assays performed / not performed on each patient.
ALT, alanine transferase (normal range 10–45 IU / L), Histology – Ishak score; F, fibrosis; I, inflammation; MLR, mixed leukocyte reaction; ND, not done; IFN-α: 6-month course.